fbpx

ADVERTISEMENT

ADVERTISEMENT

Candidiasis

Updated : October 28, 2022





Background

Candidiasis is most commonly seen as a secondary infection in immunocompromised patients. Thrush is the common name for candidiasis of the mouth. It appears as white patches on the throat, tongue, and other mouth areas.

Other symptoms of thrush include soreness and difficulty swallowing. They only become pathogenic when favorable conditions exist. It can affect the vagina, mouth, penis, and other body areas.

Epidemiology

Candidiasis is prevalent in infancy and old age. Thrush affects approximately 37% of newborns in the United States. Oral candidiasis is common in children with a history of inhaled steroids. It is common in women during pregnancy. Thrush could be the first sign of HIV infection.

Thrush is widespread and more common in undernourished populations and affects both men and women equally. Even though Candida albicans is the predominant cause of candidiasis, non-Candida species have risen in recent years.

It is critical to understand non-albicans species because treatment varies according to species. Fluconazole resistance may exist in Candida species other than Albicans. Invasive and disseminative candidiasis is becoming more common worldwide, and individuals with compromised immune systems are particularly vulnerable.

Anatomy

Pathophysiology

Candida enters the bloodstream via three routes: the most common is through the gastrointestinal tract mucosal barrier, followed by an intravascular catheter and a localized infection. Candida can enter the bloodstream of both neutropenic and intensive care unit patients. They are also a normal part of the gut microflora, and a person immunocompromised status can lead to bloodstream candidiasis.

Candida growth in indwelling catheters, particularly central lines, can occur at either the implantation site or the hub, leading to the subsequent Candida infection. Candida albicans typically colonize thrush in neonates during the passage via the infected vagina, with an active vaginal yeast infection, the neonate’s chances of developing thrush increase.

The use of local or systemic antimicrobial therapy may precipitate vulvovaginal candidiasis, and it may also polymerize frequent episodes of disease. Bloodstream invasion from a localized infection is uncommon, but it is common with ascending Candida urinary tract infections associated with either innate obstruction or external compression.

Etiology

Candida albicans cause mucosal candidiasis when present in an immunocompromised host. Patients with leukemia or lymphoma who have been administered corticosteroids or cytotoxic drugs have deteriorated immunity, which leads to candidal infection. Antibiotic use is frequently linked to candidiasis.

Cancer cytotoxic chemotherapy can cause Candida albicans fungemia, which develops from fungal translocation via vulnerable mucosal barriers. Due to changes in intrinsic bacterial composition or population and the host environment, fungi in the upper and lower GI tract can develop opportunistic pathogens.

Pregnancy, diabetes mellitus, and oral contraceptives increase vaginal colonization. Oral candidiasis is strongly linked to HIV patients. Candida infection affects more than 90% of HIV patients.

Myxedema, tuberculosis, hypoparathyroidism, nutritional deficiency, Addison’s disease, smoking, IV tubes, poorly maintained dentures, catheters, heart valves, infancy, pregnancy, and old age are all risk factors for candidiasis. Because of the lack of protective antifungal proteins, histatin, and calprotectin, xerostomia is also a risk factor.

Genetics

Prognostic Factors

Untreated Candida infections can spread to other organs and cause a systemic infection. The long-term prognosis of systemic candidiasis is determined by the severity and site of the Candida infection, the infected person’s overall health, and the timeframe of diagnosis and treatment.

Almost one-third of candidemia patients develop septic shock due to host factors such as age and source of infection rather than intrinsic virulence variables of organisms.

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

 

fluconazole 

Oesophageal candidiasis
200mg orally on day 1, then 100mg every day

Oropharyngeal candidiasis
200mg orally on day 1, then 100mg every day

Prophylaxis of candidiasis with bone marrow transplantation
400mg orally every day



fluconazole 

Indicated for candida UTI/peritonitis:

50-200mg orally every day



butoconazole 

5g of the cream (1 applicatorful of cream) administered intravaginally as a single dose
Extend the dose for 6 days only in the second and third trimesters of pregnancy (Not recommended in the first trimester)



micafungin 

Esophageal Candidiasis
150mg/day intravenous administration for 10 to 30 days

Candida Infections in HSCT Recipients Prophylaxis
50mg/day intravenous administration for 6 to 51 days

Treatment of acute disseminated candidiasis, candidemia, abscesses, and candida peritonitis
100mg/day intravenous administration for 10 to 47 days



flucytosine 

50-150 mg/kg orally each day divided every 6 hours
Take the dose with a plenty glass full of water
In the case of renal impairment, adjust the dose
If more than one capsule is taken, keep a gap of 15 minutes between each swallow to prevent vomiting and nausea



 

fluconazole 

Oropharyngeal candidiasis
6mg/kg orally on day 1, then 3mg/kg daily
Do not exceed 600mg/day

Oesophageal candidiasis
6mg/kg orally on day 1, then 3mg/kg daily
Do not exceed 600mg/day

Systemic candida infections
6-12mg/kg/day orally or intravenously. Do not exceed 600mg/day



micafungin 

Four months and older
Esophageal Candidiasis
>30 kgs: 2.5 mg/kg intravenous every day. Do not exceed 150mg/day
≤30 kgs: 3 mg/kg intravenous every day

Candida Infections in HSCT Recipients Prophylaxis
1 mg/kg intravenous every day. Do not exceed 50mg/day

Treatment of acute disseminated candidiasis, candidemia, abscesses, and candida peritonitis
2 mg/kg intravenous every day. Do not exceed 100mg/day

younger than four months old
4mg/kg intravenous everyday



flucytosine 

For children- 50-150 mg/kg orally each day divided every 6 hours
For neonates (less than 28 years old)- 80-160 mg/kg orally each day divided every 6 hours
In the case of renal impairment, adjust the dose



 

Media Gallary

References

https://www.ncbi.nlm.nih.gov/books/NBK560624/

ADVERTISEMENT 

Candidiasis

Updated : October 28, 2022




Candidiasis is most commonly seen as a secondary infection in immunocompromised patients. Thrush is the common name for candidiasis of the mouth. It appears as white patches on the throat, tongue, and other mouth areas.

Other symptoms of thrush include soreness and difficulty swallowing. They only become pathogenic when favorable conditions exist. It can affect the vagina, mouth, penis, and other body areas.

Candidiasis is prevalent in infancy and old age. Thrush affects approximately 37% of newborns in the United States. Oral candidiasis is common in children with a history of inhaled steroids. It is common in women during pregnancy. Thrush could be the first sign of HIV infection.

Thrush is widespread and more common in undernourished populations and affects both men and women equally. Even though Candida albicans is the predominant cause of candidiasis, non-Candida species have risen in recent years.

It is critical to understand non-albicans species because treatment varies according to species. Fluconazole resistance may exist in Candida species other than Albicans. Invasive and disseminative candidiasis is becoming more common worldwide, and individuals with compromised immune systems are particularly vulnerable.

Candida enters the bloodstream via three routes: the most common is through the gastrointestinal tract mucosal barrier, followed by an intravascular catheter and a localized infection. Candida can enter the bloodstream of both neutropenic and intensive care unit patients. They are also a normal part of the gut microflora, and a person immunocompromised status can lead to bloodstream candidiasis.

Candida growth in indwelling catheters, particularly central lines, can occur at either the implantation site or the hub, leading to the subsequent Candida infection. Candida albicans typically colonize thrush in neonates during the passage via the infected vagina, with an active vaginal yeast infection, the neonate’s chances of developing thrush increase.

The use of local or systemic antimicrobial therapy may precipitate vulvovaginal candidiasis, and it may also polymerize frequent episodes of disease. Bloodstream invasion from a localized infection is uncommon, but it is common with ascending Candida urinary tract infections associated with either innate obstruction or external compression.

Candida albicans cause mucosal candidiasis when present in an immunocompromised host. Patients with leukemia or lymphoma who have been administered corticosteroids or cytotoxic drugs have deteriorated immunity, which leads to candidal infection. Antibiotic use is frequently linked to candidiasis.

Cancer cytotoxic chemotherapy can cause Candida albicans fungemia, which develops from fungal translocation via vulnerable mucosal barriers. Due to changes in intrinsic bacterial composition or population and the host environment, fungi in the upper and lower GI tract can develop opportunistic pathogens.

Pregnancy, diabetes mellitus, and oral contraceptives increase vaginal colonization. Oral candidiasis is strongly linked to HIV patients. Candida infection affects more than 90% of HIV patients.

Myxedema, tuberculosis, hypoparathyroidism, nutritional deficiency, Addison’s disease, smoking, IV tubes, poorly maintained dentures, catheters, heart valves, infancy, pregnancy, and old age are all risk factors for candidiasis. Because of the lack of protective antifungal proteins, histatin, and calprotectin, xerostomia is also a risk factor.

Untreated Candida infections can spread to other organs and cause a systemic infection. The long-term prognosis of systemic candidiasis is determined by the severity and site of the Candida infection, the infected person’s overall health, and the timeframe of diagnosis and treatment.

Almost one-third of candidemia patients develop septic shock due to host factors such as age and source of infection rather than intrinsic virulence variables of organisms.

fluconazole 

Oesophageal candidiasis
200mg orally on day 1, then 100mg every day

Oropharyngeal candidiasis
200mg orally on day 1, then 100mg every day

Prophylaxis of candidiasis with bone marrow transplantation
400mg orally every day



fluconazole 

Indicated for candida UTI/peritonitis:

50-200mg orally every day



butoconazole 

5g of the cream (1 applicatorful of cream) administered intravaginally as a single dose
Extend the dose for 6 days only in the second and third trimesters of pregnancy (Not recommended in the first trimester)



micafungin 

Esophageal Candidiasis
150mg/day intravenous administration for 10 to 30 days

Candida Infections in HSCT Recipients Prophylaxis
50mg/day intravenous administration for 6 to 51 days

Treatment of acute disseminated candidiasis, candidemia, abscesses, and candida peritonitis
100mg/day intravenous administration for 10 to 47 days



flucytosine 

50-150 mg/kg orally each day divided every 6 hours
Take the dose with a plenty glass full of water
In the case of renal impairment, adjust the dose
If more than one capsule is taken, keep a gap of 15 minutes between each swallow to prevent vomiting and nausea



fluconazole 

Oropharyngeal candidiasis
6mg/kg orally on day 1, then 3mg/kg daily
Do not exceed 600mg/day

Oesophageal candidiasis
6mg/kg orally on day 1, then 3mg/kg daily
Do not exceed 600mg/day

Systemic candida infections
6-12mg/kg/day orally or intravenously. Do not exceed 600mg/day



micafungin 

Four months and older
Esophageal Candidiasis
>30 kgs: 2.5 mg/kg intravenous every day. Do not exceed 150mg/day
≤30 kgs: 3 mg/kg intravenous every day

Candida Infections in HSCT Recipients Prophylaxis
1 mg/kg intravenous every day. Do not exceed 50mg/day

Treatment of acute disseminated candidiasis, candidemia, abscesses, and candida peritonitis
2 mg/kg intravenous every day. Do not exceed 100mg/day

younger than four months old
4mg/kg intravenous everyday



flucytosine 

For children- 50-150 mg/kg orally each day divided every 6 hours
For neonates (less than 28 years old)- 80-160 mg/kg orally each day divided every 6 hours
In the case of renal impairment, adjust the dose



https://www.ncbi.nlm.nih.gov/books/NBK560624/

Free CME credits

Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.

Digital Certificate PDF

On course completion, you will receive a full-sized presentation quality digital certificate.

medtigo Simulation

A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.

medtigo Points

medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
 
  • Registration with medtigo = 10 points
  • 1 visit to medtigo’s website = 1 point
  • Interacting with medtigo posts (through comments/clinical cases etc.) = 5 points
  • Attempting a game = 1 point
  • Community Forum post/reply = 5 points

    *Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.

All Your Certificates in One Place

When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.

Our Certificate Courses